Microbiome analysis combined with targeted metabolomics reveal immunological anti-tumor activity of icariside I in a melanoma mouse model

Biomedicine & Pharmacotherapy

Jinlin Zhou¹  Hehua Lei¹  Zheng Cao¹  Caixiang Liu¹  Yujing Lu²  Gui Chen²  Limin Zhang²  Yuchen Song²  Chuan Chen²  Zunji Shi²  Manyuan Dong²  Peihong Yuan²  Fang Wu² 

[1] University of Chinese Academy of Sciences, Beijing 100049, China;Chinese Academy of Sciences (CAS) Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Centre for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy of Precision Measurement Science and Technology, CAS, Wuhan 430071, China;

关键词: Melanoma;    Icariside I;    Gut microbiota;    Systematic immunity;    Metabolomics;   

DOI  :  

来源: DOAJ

【 摘 要 】

Recent studies report that the gut microbiome can enhance systemic and antitumor immunity by modulating responses to antibody immunotherapy in melanoma patients. In this study, we found that icariside I, a novel anti-cancer agent isolated from Epimedium, significantly inhibited B16F10 melanoma growth in vivo through regulation of gut microbiota and host immunity. Oral administration of icariside I improved the microbiota community structure with marked restoration of Lactobacillus spp. and Bifidobacterium spp. abundance in the cecal contents of tumor-bearing mice. We also found that icariside I improves the levels of microbiota-derived metabolites such as short-chain fatty acids (SCFAs) and indole derivatives, consequently promoting repair of the intestinal barrier and reducing systemic inflammation of tumor-bearing mice. Icariside I exhibited strong immunological anti-tumor activity, directly manifested by up-regulation of multiple lymphocyte subsets including CD4+ and CD8+ T cells or NK and NKT cells in peripheral blood of tumor-bearing mice. Collectively, these results suggest that icariside I, via its microbiome remodeling and host immune regulation properties, may be developed as an anticancer drug.

【 授权许可】

Unknown